At 48 hours post-treatment, an elevation in anti-tumor macrophage activation markers was observed, with increases in expression of MHCII, co-stimulatory markers CD86 and CD80, PDL1 and the migratory marker CCR7 (Figure 2A). This evidence concerns the gene CD86 and neoplasm.